UNSPSC 51142427: Eletriptan hydrobromide

This classification denotes a serotonin agonist with the molecular formula C22H26N2O2S.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M41W832TA3, chemically known as 1h-indole, 3-(((2r)-1-methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-, monohydrobromide but more generally known as eletriptan hydrobromide, which bears US NIH Compound Identifier 156849. European Medicines Agency schedules Eletriptan hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26382.

UNSPSC 51142427 Eletriptan hydrobromide is a Commodity code with minimal alignment to recent state and local procurement activity. The code nominally names a specific pharmaceutical active ingredient (eletriptan hydrobromide, a triptan used to treat migraine headaches), yet the three most recent opportunities posted under or near this code span naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceutical supply — none of which target eletriptan specifically. State and local governments buying under this code appear to source pharmaceuticals through cooperative purchasing vehicles and health department channels rather than through direct ingredient specification, and issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances.

Activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through its e-Procurement Portal, with quarterly deliveries to the county community health building and E-Verify compliance required. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program, seeking information on vendors' experience with self-insured employer and government health plan contracting and outcomes-based agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers, maintain cGMP and DSCSA compliance, and accept a 3 percent administrative fee. The code shows little direct recent activity tied to eletriptan as a single-drug procurement target.